Nutraceuticals in hypercholesterolaemia: an overview
- PMID: 27685833
- PMCID: PMC5429323
- DOI: 10.1111/bph.13636
Nutraceuticals in hypercholesterolaemia: an overview
Abstract
Growing attention is now being given to the possible preventive/alternative ways to avoid illness onset. Changes in lifestyle and food habits are taking over from the conventional pharmaceutical-based approach, especially for chronic pathologies. Nutraceuticals have been proposed as key tools for the prevention and cure of some pathological conditions. This is leading research to develop new formulations based on these pharma-foods addressed in a specific way to prevent and cure health issues, which, in turn, will have an effect on therapy-related costs sustained by any National Health Organization. According to existing regulations, nutraceuticals cannot be categorized as either food or drugs but, by definition, often inhabit a grey area in between the two, being assimilated into food supplements, notwithstanding the beneficial properties that they can provide for some pathological conditions. A nutraceuticals-based approach for health management, in particular for some pathological conditions, has resulted in a worldwide growing 'nutraceutical' revolution. An outstanding example is the approach to the 'metabolic syndrome', which includes overweight, obesity and cardiovascular-related diseases, causing a sort of cascade of chronic health conditions, which is becoming a norm in modern life. Hypercholesterolaemia is one of these. It represents an example of a pathology that can be linked to both a poor lifestyle and dietary habits. The nutraceutical approach to hypercholesterolaemia is described in the present review as a possible alternative to the conventional drug-based therapy.
Linked articles: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc.
© 2016 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Figures
References
-
- Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ (2008). Statins for secondary prevention in elderly patients. J Am Coll Cardiol 51: 37–45. - PubMed
-
- Agostoni C, Bresson JL, Fairweather‐Tait S, Flynn A, Golly I, Korhonen H et al. (2011a). Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 9: 2304–2320.
-
- Agostoni C, Bresson JL, Fairweather‐Tait S, Flynn A, Golly I, Korhonen H et al. (2011b). Scientific opinion on the substantiation of health claims related to beta‐glucans from oats and barley and maintenance of normal blood LDL‐cholesterol concentrations (ID 1236, 1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post‐prandial glycaemic responses (ID 821, 824), and “digestive function” (ID 850) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA J 9: 2207.
-
- Alonso‐Salces RM, Ndjoko K, Queiroz EF, Ioset JR, Hostettmann K, Berrueta LA et al. (2004). On‐line characterisation of apple polyphenols by liquid chromatography coupled with mass spectrometry and ultraviolet absorbance detection. J Chromatogr A 1046: 89–100. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
